menu
    • menu
    [{"orgOrder":0,"company":"Antabio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ANT3310","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Antabio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Antabio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Antabio \/ Not Applicable"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Meropenem","moa":"D-alanyl-D-alanine carboxypeptidase DacB","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Melinta Therapeutics \/ Hikma Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Melinta Therapeutics \/ Hikma Pharmaceutical"},{"orgOrder":0,"company":"Antabio","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"ANT3310","moa":"Serine beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Antabio","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Intravenous","sponsorNew":"Antabio \/ Bpifrance","highestDevelopmentStatusID":"4","companyTruncated":"Antabio \/ Bpifrance"},{"orgOrder":0,"company":"Sumitovant Biopharma","sponsor":"Sumitomo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"KSP-1007","moa":"Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sumitovant Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sumitovant Biopharma \/ Sumitomo Dainippon Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Sumitovant Biopharma \/ Sumitomo Dainippon Pharma"},{"orgOrder":0,"company":"Menarini","sponsor":"SciClone","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Meropenem","moa":"Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Menarini","amount2":0.11,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.11,"dosageForm":"Injectable\/Injection","sponsorNew":"Menarini \/ SciClone","highestDevelopmentStatusID":"12","companyTruncated":"Menarini \/ SciClone"},{"orgOrder":0,"company":"Aceragen","sponsor":"Idera Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Sodium Fusidate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aceragen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Aceragen \/ Idera Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Aceragen \/ Idera Pharmaceuticals"},{"orgOrder":0,"company":"Qpex Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Xeruborbactam","moa":"Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Qpex Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Qpex Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Qpex Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ribaxamase","moa":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Theriva Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Antabio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ANT3310","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Antabio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Antabio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antabio \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Meropenem

    Menu

    Meropenem

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Antabio

                            France arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Antabio

                            France arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANT3310,Meropenem

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Antabio Announces First Subjects Dosed in Phase 1 Clinical Trial of MEM-ANT3310, a Highly Differentiated Antib...

                            Details : MEM-ANT3310 combines the well-known carbapenem meropenem (MEM) with ANT3310, a breakthrough serine-beta-lactamase (SBL) inhibitor.

                            Brand Name : MEM-ANT3310

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 25, 2023

                            Lead Product(s) : ANT3310,Meropenem

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Theriva Biologics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Theriva Biologics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ribaxamase,Meropenem

                            Therapeutic Area : Immunology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Theriva Biologics Announces First Patient Dosed in Second Cohort of Phase 1b/2a Clinical Trial of SYN-004 (rib...

                            Details : SYN-004 (ribaxamase), is an oral prophylactic therapy designed to degrade certain IV beta-lactam antibiotics within GI tract, thereby preventing antibiotic-mediated damage to the gut microbiome and reducing adverse outcomes associated with antibiotic-med...

                            Brand Name : SYN-004

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 03, 2022

                            Lead Product(s) : Ribaxamase,Meropenem

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Qpex Biopharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Qpex Biopharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Xeruborbactam,Meropenem

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Qpex Biopharma Announces Presentations on Phase 1 and Nonclinical Data on Three Clinical Stage Oral and IV Pro...

                            Details : ORAvance (Xeruborbactam) an orally-administered combination product that delivers xeruborbactam to treat infections that occur in outpatient and community setting caused by drug-resistant gram-negative bacteria.

                            Brand Name : ORAvance

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 17, 2022

                            Lead Product(s) : Xeruborbactam,Meropenem

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Aceragen

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Aceragen

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Fusidate,Ceftazidime,Meropenem

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Idera Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Idera Pharmaceuticals Acquires Aceragen

                            Details : The combined cash of the two companies is expected to provide runway into Q3 2023, funding the advancement of Aceragen’s pipeline, including ACG-701 (sodium fusidate) and ACG-801, through important 2023 clinical milestones.

                            Brand Name : ACG-701

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 28, 2022

                            Lead Product(s) : Sodium Fusidate,Ceftazidime,Meropenem

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Idera Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Menarini

                            Italy arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Menarini

                            Italy arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Meropenem,Vaborbactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : SciClone

                            Deal Size : $113.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Menarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem® in China to Tr...

                            Details : Under the License Agreement, SciClone will be responsible for conducting and funding local clinical development as well as commercialization of Vaborem® (meropenem). To facilitate patients in China, SciClone will conduct local clinical trials and pursue...

                            Brand Name : Vaborem

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 20, 2022

                            Lead Product(s) : Meropenem,Vaborbactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : SciClone

                            Deal Size : $113.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sumitovant Biopharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Sumitovant Biopharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KSP-1007,Meropenem

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Sumitomo Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sumitomo Dainippon Pharma and Sumitovant Biopharma Initiate Phase 1 Study on New Drug Candidate for Carbapenem...

                            Details : It appears from nonclinical data that KSP-1007 broadly and strongly inhibits β-lactamases, which are enzymes that are produced by bacteria that can degrade carbapenem antibiotics. Sumitovant is leading the program of the compound in the U.S.

                            Brand Name : KSP-1007

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 10, 2022

                            Lead Product(s) : KSP-1007,Meropenem

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Sumitomo Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Antabio

                            France arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Antabio

                            France arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANT3310,Meropenem

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Bpifrance

                            Deal Size : $10.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            French Multidisciplinary Consortium ARPEGE Awarded Public Funding of Close To €9 Million to Fight Antibiotic...

                            Details : The funding for Antabio will allow to continue the development of ANT3310 towards clinical studies and reach crucial milestones such as the clinical demonstration of its safety and tolerability in humans.

                            Brand Name : ANT3310

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 06, 2022

                            Lead Product(s) : ANT3310,Meropenem

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Bpifrance

                            Deal Size : $10.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Melinta Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Melinta Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Meropenem,Vaborbactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Hikma Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Melinta Therapeutics and Hikma Sign Exclusive Licensing Agreement for Two Novel Anti-Infectives for the Middle...

                            Details : Under the terms of the deal, Hikma will responsible for the registration and commercialization of Orbactiv and Vabomere across its 18 MENA markets. This extends Hikma’s existing partnership with Melinta for their intravenous and oral formulations of Ba...

                            Brand Name : Vabomere

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 29, 2021

                            Lead Product(s) : Meropenem,Vaborbactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Hikma Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Antabio

                            France arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Antabio

                            France arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANT3310,Meropenem

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Antabio Receives QIDP Designation From the U.S. FDA for the Development of MEM-ANT3310

                            Details : QIDP is granted to Antabio's MEM-ANT3310 for major hospital indications including nosocomial pneumonia.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 06, 2020

                            Lead Product(s) : ANT3310,Meropenem

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth